Relapsed or Refractory Multiple Myeloma: Eftozanermin Alfa (ABBV-621) with Bortezomib and Dexamethasone

Clinical Trial Grant

Duke Scholars

Principal Investigator Cristina Gasparetto Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

August 23, 2021

End Date

January 23, 2024

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

August 23, 2021

End Date

January 23, 2024